超血症对心力衰竭和减少喷射率的影响:一项回顾性研究
Andrea Lopez-López1,2, Raúl Franco-Gutiérrez1,2, Alberto José Pérez-Pérez1,2
1Cardiology Department, Hospital Universitario Lucus Augusti, 27003 Lugo, Spain.
Journal of clinical medicine
|May 27, 2023
概括
超血症在心力衰竭中很常见,患者的喷射率减少 (HFrEF). 通常高水平 (5-5.5mEq/L) 似乎是安全的,并且与HFrEF中死亡率的增加无关.
科学领域:
- 心脏病学 心脏病学
- 腎臟病學 (nephrology) 是一種醫學專業.
- 内部医学 内部医学
背景情况:
- 超血是心力衰竭和减少喷射率 (HFrEF) 的患者经常出现的并发症.
- 在HFrEF患者中高血和最佳水平的预后意义仍然是争论的主题.
- 这项研究旨在调查HFrEF中高血症的发病率,预测因素和死亡率的影响.
研究的目的:
- 为了确定HFrEF患者队列中的5年超血病的发病率.
- 在这个患者群体中识别高卡利米亚的预测因子.
- 评估高胆固醇血对整体5年死亡率的影响.
主要方法:
- 一个回顾性,纵向的,单中心的观察性研究.
- 从2011年到2019年,在一个专门的单位跟踪包括HFrEF患者.
- 超血症的定义是度>5.5mEq/L.
主要成果:
- 在1013名HFrEF患者中,16.8%的患者出现过高血症,无过高血症的5年生存率为82.1%.
- 高血症的预测因素包括较高的基线,较低的肌素清除率,较差的右心室功能和糖尿病.
- 正常高水平 (5-5.5mEq/L) 与死亡率相反相关 (HR 0.60,95%CI 0.38-0.94;p = 0.025).
结论:
- 高血是HFrEF患者的一个重要发现,可能会影响神经激素治疗优化.
- 在这个队列中,正常高范围 (5-5.5mEq/L) 的水平被认为是安全的.
- 需要进一步的研究来确定HFrEF中最佳的管理策略.
相关概念视频
01:17Pathophysiology of Heart Failure
1.7K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.7K
01:29Heart Failure II: Pathophysiology
16
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
16
01:27Heart Failure I: Introduction
24
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
24
01:22Heart Failure Drugs: Diuretics
430
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
430
01:30Heart Failure V: Medical Management
16
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
16
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
471
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
471